UCL logo

UCL Discovery

UCL home » Library Services » Electronic resources » UCL Discovery

Browse by UCL Departments and Centres

Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Author | Type
Jump to: A | B | C | D | F | G | H | J | K | L | M | N | P | R | S | T | V | W
Number of items: 91.

A

Anderson, FM; O'Hare, CC; Hartley, JA; Robins, DJ; (2000) Synthesis of new homochiral bispyrrolidines as potential DNA cross-linking antitumour agents. ANTI-CANCER DRUG DES , 15 (2) 119 - 126.

Arkenau, HT; Hegglin, I; Lüthi, U; (2000) [Trichosporosis]. Schweiz Med Wochenschr , 130 (49) 1914-.

Arkenau, HT; Lüthi, U; (2000) [Amyloidoma]. Schweiz Med Wochenschr , 130 (35) 1244-.

Arris, CE; Boyle, FT; Calvert, AH; Curtin, NJ; Endicott, JA; Garman, EF; Gibson, AE; (2000) Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles. J MED CHEM , 43 (15) 2797 - 2804.

Azzabi, AS; Calvert, AH; Verrill, M; Kelly, C; Lind, MJ; Newell, DR; Griffin, MJ; (2000) Phase I and pharmacokinetic study of temozolomide and paclitaxel in the treatment of malignant melanoma. Clinical Cancer Research , 6 539 - ?.

B

Barlow, HC; Bowman, KJ; Curtin, NJ; Calvert, AH; Golding, BT; Huang, B; Loughlin, PJ; (2000) Resistance-modifying agents. Part 7: 2, 6-disubstituted-4,8-dibenzylaminopyrimido[5,4-d]pyrimidines that inhibit nucleoside transport in the presence of alpha(1)-acid glycoprotein (AGP). BIOORG MED CHEM LETT , 10 (6) 585 - 589.

Baynes, KCR; Beeton, CA; Panayotou, G; Stein, R; Soos, M; Hansen, T; Simpson, H; (2000) Natural variants of human p85 alpha phosphoinositide 3-kinase in severe insulin resistance: a novel variant with impaired insulin-stimulated lipid kinase activity. DIABETOLOGIA , 43 (3) pp. 321-331. 10.1007/s001250050050.

Bentley, J; Arris, CE; Boyle, FT; Calvert, AH; Curtin, NJ; Endicott, JA; Gibson, AE; (2000) Structure-activity relationships and cellular effects of novel purine- and pyrimidine-based cyclin dependent kinase inhibitors. Clinical Cancer Research , 6 328 - ?.

Bhatia, J; Sharma, SK; Chester, KA; Pedley, RB; Boden, RW; Read, DA; Boxer, GM; (2000) Catalytic activity of an in vivo tumor targeted anti-CEA scFv::carboxypeptidase G2 fusion protein. Int J Cancer , 85 (4) pp. 571-577.

Bhatia, J; Sharma, SK; Chester, KA; Pedley, RB; Boden, RW; Read, DA; Boxer, GM; (2000) Catalytic activity of an in vivo tumor targeted anti-CEA scFv :: carboxypeptidase G2 fusion protein. INT J CANCER , 85 (4) 571 - 577.

Bhatia, J; Sharma, SK; Pedley, BR; Boxer, G; Robson, L; Begent, RHJ; Chester, K; (2000) In vitro & in vivo stability of purified MFE 23 :: CPG2 fusion protein from Pichia pastoris. In: (pp. p. 71). CHURCHILL LIVINGSTONE

Boddy, AV; Griffin, MJ; Wright, JG; Sludden, JA; Thomas, HD; Fishwick, K; Plummer, R; (2000) Paclitaxel and carboplatin dose-intensity and duration of infusion in the treatment of ovarian cancer. British Journal of Cancer , 83 203 - ?.

Boehm, MK; Corper, AL; Wan, T; Sohi, MK; Sutton, BJ; Thornton, JD; Keep, PA; (2000) Crystal structure of the anti-(carcinoembryonic antigen) single-chain Fv antibody MFE-23 and a model for antigen binding based on intermolecular contacts. Biochem J , 346 Pt pp. 519-528.

Broadstock, M; Michie, S; Gray, J; Mackay, J; Marteau, TM; (2000) The psychological consequences of offering mutation searching in the family for those at risk of hereditary breast and ovarian cancer - A pilot study. PSYCHO-ONCOL , 9 (6) 537 - 548.

Brooks, N; McHugh, PJ; Lee, M; Hartley, JA; (2000) Alteration in the choice of DNA repair pathway with increasing sequence selective DNA alkylation in the minor groove. CHEM BIOL , 7 (9) 659 - 668.

C

Calabrese, CR; Curtin, NJ; Canan-Koch, SS; Batey, MA; Thomas, HD; Kyle, S; Wang, LZ; (2000) Design and evaluation of novel potent inhibitors of poly(ADP-ribose) polymerase. Clinical Cancer Research , 6 150 - ?.

Calvert, P; Jayson, G; Atkinson, R; Ganesan, T; Cervantes-Ruiperez, A; Vasey, P; Adams, M; (2000) Phase II clinical and pharmacokinetic study of exatecan mesylate (DX-8951f) in patients with advanced ovarian cancer, refractory to, or relapsed after platinum and taxane. Annals of Oncology , 11 372P - ?.

Calvert, PM; O'Neill, V; Azzabi, A; Hughes, A; Plummer, R; Twelves, C; Robinson, A; (2000) A phase I clinical and pharmacokinetic study of EPO906 (epothilone B) in patients with advanced solid tumours. Clinical Cancer Research , 6 575 - ?.

Cerone, MA; Marchetti, A; Bossi, G; Blandino, G; Sacchi, A; Soddu, S; (2000) p53 is involved in the differentiation but not in the differentiation-associated apoptosis of myoblasts. Cell Death Differ , 7 (5) pp. 506-508. 10.1038/sj.cdd.4400676.

Chester, KA; Bhatia, J; Boxer, G; Cooke, SP; Flynn, AA; Huhalov, A; Mayer, A; (2000) Clinical applications of phage-derived sFvs and sFv fusion proteins. DISEASE MARKERS , 16 (1-2) 53 - 62.

Chester, KA; Mayer, A; Bhatia, J; Robson, L; Spencer, DI; Cooke, SP; Flynn, AA; (2000) Recombinant anti-carcinoembryonic antigen antibodies for targeting cancer. Cancer Chemother Pharmacol , 46 Sup S8-12.

Chester, KA; Mayer, A; Bhatia, J; Robson, L; Spencer, DIR; Cooke, SP; Flynn, AA; (2000) Recombinant anti-carcinoembryonic antigen antibodies for targeting cancer. In: CANCER CHEMOTHERAPY AND PHARMACOLOGY. (pp. S8 - S12). SPRINGER-VERLAG

Cooke, SP; Boxer, GM; Spencer, DIR; Lawrence, L; Pedley, RB; Chester, KA; Begent, RHJ; (2000) Tumour vascular targeting using a novel anti-vascular endothelial cell growth factor (VEGF) scFv antibody. British Journal of Cancer , 83 (Suppl) 14-.

Cooke, SP; Boxer, GM; Spencer, DIR; Lawrence, L; Pedley, RB; Chester, KA; Begent, RHJ; (2000) Tumour vascular targeting using a novel anti-vascular endothelial cell growth factor (VEGF) scFv antibody. BRIT J CANCER , 83 11 - 11.

Coulonval, K; Vandeput, F; Stein, RC; Kozma, SC; Lamy, F; Dumont, JE; (2000) Phosphatidylinositol 3-kinase, protein kinase B and ribosomal S6 kinases in the stimulation of thyroid epithelial cell proliferation by cAMP and growth factors in the presence of insulin. Biochem J , 348 Pt pp. 351-358.

Curtin, NJ; Calvert, AH; Canan-Koch, S; Durkacz, BW; Griffin, RJ; Golding, BT; Hostomsky, Z; (2000) Chemopotentiation studies with two classes of potent (polyADP-ribose) polymerase (PARP) inhibitors in human lung and colon carcinoma cell lines. Clinical Cancer Research , 6 205 - ?.

D

De Silva, IU; McHugh, PJ; Clingen, PH; Hartley, JA; (2000) Defining the roles of nucleotide excision repair and recombination in the repair of DNA interstrand cross-links in mammalian cells. MOL CELL BIOL , 20 (21) 7980 - 7990.

Dearling, JLJ; Flynn, AA; Pagoulatos, C; Wilson, GD; Woodcock, M; Denholm, E; Hartley, J; (2000) Influence of tumour cell response and nuclide selection on the efficacy of RIT. British Journal of Cancer , 83 (Suppl) 173-.

Dearling, JLJ; Flynn, AA; Pagoulatos, C; Wilson, GD; Woodcock, M; Denholm, E; Hartley, J; (2000) Influence of tumour cell response and nuclide selection on the efficacy of RIT. In: BRIT J CANCER. (pp. 72 - 72). CHURCHILL LIVINGSTONE

Delaney, CA; Wang, LZ; Kyle, S; White, AW; Calvert, AH; Curtin, NJ; Durkacz, BW; (2000) Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines. CLIN CANCER RES , 6 (7) 2860 - 2867.

Dey, A; McCloskey, EV; Taube, T; Cox, R; Pande, KC; Ashford, RU; Forster, M; (2000) Metacarpal morphometry using a semi-automated technique in the assessment of osteoporosis and vertebral fracture risk. Osteoporos Int , 11 (11) pp. 953-958. 10.1007/s001980070034.

Di Francesco, AM; Hargreaves, RHJ; Wallace, TW; Mayalarp, SP; Hazrati, A; Hartley, JA; Butler, J; (2000) Anti-tumour properties of novel diaziridinylquinones. BRIT J CANCER , 83 66 - 66.

Di Francesco, AM; Hargreaves, RHJ; Wallace, TW; Mayalarp, SP; Hazrati, A; Hartley, JA; Butler, J; (2000) Anti-tumour properties of novel diaziridinylquinones. CLIN CANCER RES , 6 4527S - 4527S.

Di Francesco, AM; Hargreaves, RHJ; Wallace, TW; Mayalarp, SP; Hazratis, A; Hartley, JA; Butler, J; (2000) The abnormal cytotoxicities of 2,5-diaziridinyl-1,4-benzoquinone-3-phenyl esters. ANTI-CANCER DRUG DES , 15 (5) 347 - 359.

Duchesne, GM; Bolger, JJ; Griffiths, GO; Trevor Roberts, J; Graham, JD; Hoskin, PJ; Fossâ, SD; (2000) A randomized trial of hypofractionated schedules of palliative radiotherapy in the management of bladder carcinoma: results of medical research council trial BA09. Int J Radiat Oncol Biol Phys , 47 (2) pp. 379-388.

Dunlop, DJ; Connery, L; O, BM; Thatcher, N; Lee, SM; Hill, S; Thatcher, N; (2000) Phase II study of carboplatin and vinorelbine in small cell lung cancer. In: (Proceedings) 2000 ASCO Annual Meeting/36th Annual Meeting, New Orleans, LA.. (pp. 518a-). Proceedings of the American Society of Clinical Oncology

Dunlop, DJ; O'Brien, ME; Lee, SM; Hill, S; Thatcher, N; (2000) Multicentre phase II study of carboplatin (AUC 5) and vinorelbine in small cell lung cancer (SCLC). In: (pp. p. 42). CHURCHILL LIVINGSTONE

F

Friedman, HS; Kerby, T; Calvert, H; (2000) Temozolomide and treatment of malignant glioma. CLIN CANCER RES , 6 (7) 2585 - 2597.

G

Gibson, V; Anderson, RJ; Hartley, JA; McAdam, SR; Cairns, D; (2000) Anthraquinone-oligodeoxynucleotide conjugates as inhibitors of gene transcription. J PHARM PHARMACOL , 52 (6) 599 - 602.

Griffin, RJ; Arris, CE; Bleasdale, C; Boyle, FT; Calvert, AH; Curtin, NJ; Dalby, C; (2000) Resistance-modifying agents. 8. Inhibition of O-6-alkylguanine-DNA alkyltransferase by O-6-alkenyl-, O-6-cycloalkenyl-, and O-6-(2-oxoalkyl)guanines and potentiation of temozolomide cytotoxicity in vitro by O-6-(1-cyclopentenylmethyl)guanine. J MED CHEM , 43 (22) 4071 - 4083. 10.1021/jm000961o.

Griffin, RJ; Arris, CE; Calvert, AH; Curtin, NJ; Jewsbury, P; Endicott, JA; Gibson, AE; (2000) Design, synthesis, and biological evaluation of O-6-alkylguanine and O-4-alkylpyrimidine cyclin-dependent kinase inhibitors. Abstracts of Papers of the American Chemical Society , 219 296 - MEDI.

H

Hampel, C; Tolner, B; Webley, SD; Lam, E; Hartley, JA; Hochhauser, D; (2000) Role of E2F-1 in chemosensitivity to minor groove binding agents. BRIT J CANCER , 83 23 - 23.

Hargreaves, RHJ; Hartley, JA; Butler, J; (2000) Mechanisms of action of quinone-containing alkylating agents: DNA alkylation by aziridinylquinones. FRONT BIOSCI , 5 E172 - E180.

Harland, SJ; (2000) Conundrum of the hereditary component of testicular cancer. LANCET , 356 (9240) 1455 - 1456.

Hartley, JA; Hazrati, A; Hodgkinson, TJ; Kelland, LR; Khanim, R; Shipman, M; Suzenet, F; (2000) Synthesis, cytotoxicity and DNA cross-linking activity of symmetrical dimers based upon the epoxide domain of the azinomycins. CHEM COMMUN (23) 2325 - 2326.

Hartley, JA; Hazrati, A; Kelland, LR; Khanim, R; Shipman, M; Suzenet, F; Walker, LF; (2000) A Synthetic Azinomycin Analogue with Demonstrated DNA Cross-Linking Activity: Insights into the Mechanism of Action of this Class of Antitumor Agent The authors gratefully acknowledge the financial support provided by the CRC and the EPSRC. We are indebted to the EPSRC National Mass Spectrometry Centre for performing mass spectral measurements, and the EPSRC Chemical Database Service at Daresbury.1. Angew Chem Int Ed Engl , 39 (19) pp. 3467-3470.

Hartley, JA; Hazrati, A; Kelland, LR; Khanim, R; Shipman, M; Suzenet, F; Walker, LF; (2000) A synthetic azinomycin analogue with demonstrated DNA cross-linking activity: Insights into the mechanism of action of this class of antitumor agent. ANGEW CHEM INT EDIT , 39 (19) 3467 - +.

Hochhauser, D; (2000) Relevance of mitochondrial DNA in cancer. LANCET , 356 (9225) 181 - 182.

Hooshmand-Rad, R; Hajkova, L; Klint, P; Karlsson, R; Vanhaesebroeck, B; Claesson-Welsh, L; Heldin, CH; (2000) The PI 3-kinase isoforms p110(alpha) and p110(beta) have differential roles in. Journal of Cell Science , 113 207 - 214.

Hooshmand-Rad, R; Hájková, L; Klint, P; Karlsson, R; Vanhaesebroeck, B; Claesson-Welsh, L; Heldin, CH; (2000) The PI 3-kinase isoforms p110(alpha) and p110(beta) have differential roles in PDGF- and insulin-mediated signaling. J Cell Sci , 113 Pt pp. 207-214.

Horwich, A; Oliver, RTD; Wilkinson, PM; Mead, GM; Harland, SJ; Cullen, MH; Roberts, JT; (2000) A Medical Research Council randomized trial of single agent carboplatin versus etoposide and cisplatin for advanced metastatic seminoma. BRIT J CANCER , 83 (12) 1623 - 1629. 10.1054/bjoc.2000.1498.

Hughes, AN; Griffin, MJ; Newell, DR; Calvert, AH; Johnston, A; Kerr, B; Lee, C; (2000) Clinical pharmacokinetic and in vitro combination studies of nolatrexed dihydrochloride (AG337, Thymitaq (TM)) and paclitaxel. BRIT J CANCER , 82 (9) 1519 - 1527.

Hughes, AN; Griffin, MJ; Newell, DR; Calvert, AH; Johnston, A; Kerr, B; Lee, C; (2000) Clinical pharmacokinetic and in vitro combination studies of nolatrexed dihydrochloride (AG337, Thymitaq (TM)) and paclitaxel. BRIT J CANCER , 82 (9) 1519 - 1527.

J

Joiner, M; Short, S; Mayes, C; Lambin, P; Marples, B; Shah, N; Saunders, MI; (2000) Low dose hypersensitivity and induced radioresistance: Possibilities for therapy and implications for radioprotection. International Journal of Radiation Oncology Biology Physics , 46 (3) p. 692.

K

Kinashi, T; Katagiri, K; Watanabe, S; Vanhaesebroeck, B; Downward, J; Takatsu, K; (2000) Distinct mechanisms of alpha 5beta 1 integrin activation by Ha-Ras and R-Ras. J Biol Chem , 275 (29) pp. 22590-22596. 10.1074/jbc.M000633200. Gold open access

L

Lo, SK; Tolner, B; Rogers, G; Schapira, AHV; Hartley, JA; Hochhauser, D; (2000) Assessment of mitochondrial DNA damage by chemotherapeutic agents. BRIT J CANCER , 83 22 - 22.

M

Maini, MK; Gudgeon, N; Wedderburn, LR; Rickinson, AB; Beverley, PCL; (2000) Clonal expansions in acute EBV infection are detectable in the CD8 and not the CD4 subset and persist with a variable CD45 phenotype. J IMMUNOL , 165 (10) 5729 - 5737.

Mayer, A; Tsiompanou, E; O'Malley, D; Boxer, GM; Bhatia, J; Flynn, AA; Chester, KA; (2000) Radioimmunoguided surgery in colorectal cancer using a genetically engineered anti-CEA single-chain Fv antibody. CLIN CANCER RES , 6 (5) 1711 - 1719.

McHugh, PJ; Sones, WR; Hartley, JA; (2000) Repair of intermediate structures produced at DNA interstrand cross-links in Saccharomyces cerevisiae. MOL CELL BIOL , 20 (10) 3425 - 3433.

Meyer, T; Rustin, GJ; (2000) Role of tumour markers in monitoring epithelial ovarian cancer. Br J Cancer , 82 (9) pp. 1535-1538. 10.1054/bjoc.2000.1174.

Middleton, MR; Lee, SM; Aranc, ; A, ; Wood, M; Thatcher, N; Margison, GP; (2000) 06-methyguanine formation, repair protein depletion and clinical outcome with a 4 hr schedule of temozolomide in the treatment of advanced melanoma: results of a phase II study. International Journal of Cancer , 88 (3) pp. 469-473.

Middleton, MR; Lorigan, P; Owens, J; Ashcroft, L; Lee, SM; Harper, P; Thatcher, N; (2000) A randomised phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma. British Journal of Cancer , 82 (6) pp. 1158-1162.

Middleton, MR; Ranson, M; Lee, SM; Bridgewater, J; McElhinney, RS; McMurry, TBH; Thatcher, N; (2000) Phase I study of 4-bromothenylguanine (4-BTG, PaTrin 2), an alkyltransferase inactivator, and temozolomide. CLIN CANCER RES , 6 4574S - 4574S.

Middleton, MR; Ranson, M; Lee, SM; Bridgewater, J; McElhinney, RS; McMurry, TBH; Thatcher, N; (2000) Phase I study of 4-bromothenylguanine (4-BTG, PaTrin 2), an alkyltransferase inactivator, and temozolomide. In: (Proceedings) 11th NCI-EORTC-AACR Symposium on New Drugs in Cancer Therapy, Amsterdam.. (pp. 4574S-). Clinical Cancer Research

Mitjans, F; Meyer, T; Fittschen, C; Goodman, S; Jonczyk, A; Marshall, JF; Reyes, G; (2000) In vivo therapy of malignant melanoma by means of antagonists of alphav integrins. Int J Cancer , 87 (5) pp. 716-723.

N

Napier, MP; Sharma, SK; Springer, CJ; Bagshawe, KD; Green, AJ; Martin, J; Stribbling, SM; (2000) Antibody-directed enzyme prodrug therapy: efficacy and mechanism of action in colorectal carcinoma. Clin Cancer Res , 6 (3) pp. 765-772.

Napier, MP; Sharma, SK; Springer, CJ; Bagshawe, KD; Green, AJ; Martin, J; Stribbling, SM; (2000) Antibody-directed enzyme prodrug therapy: Efficacy and mechanism of action in colorectal carcinoma. CLIN CANCER RES , 6 (3) 765 - 772.

P

Pavlidis, N; Aamdal, S; Awada, A; Calvert, H; Fumoleau, P; Sorio, R; Punt, C; (2000) Carzelesin phase II study in advanced breast, ovarian, colorectal, gastric, head and neck cancer, non-Hodgkin's lymphoma and malignant melanoma: a study of the EORTC early clinical studies group (ECSG). CANCER CHEMOTH PHARM , 46 (2) 167 - 171.

Pedley, RB; Sharma, SK; Boxer, G; Flynn, AA; Boden, R; Watson, R; Dearling, J; (2000) Tumour eradication by combined antibody-directed and antivascular therapy. BRIT J CANCER , 83 13 - 13.

Porrello, A; Cerone, MA; Coen, S; Gurtner, A; Fontemaggi, G; Cimino, L; Piaggio, G; (2000) p53 regulates myogenesis by triggering the differentiation activity of pRb. J Cell Biol , 151 (6) pp. 1295-1304.

R

Raymond, EE; Fumoleau, P; Roche, H; Schellens, JHM; Dittrich, C; Punt, CJA; Droz, JP; (2000) Combined results of 4 phase I and pharmacokinetic (PK) studies of E7070, a novel chloroindolyl-sulphonamide inhibiting the activation of cdk2 and cyclin E. Clinical Cancer Research , 6 315 - ?.

Rudd, RM; Gower, NH; James, LE; Gregory, W; Eisen, TQ; Lee, SM; et, A; (2000) A phase II/III randomised comparison of gemcitabine/carboplatin (GC) with mitomycin, ifosfamide and cisplatin (MIC) in advanced non-small cell lung cancer (NSCLC). In: (Proceedings) 9th World Conference on Lung Cancer, Tokyo, Japan.. (pp. 21-). Lung Cancer

S

Saifuddin, A; Whelan, J; Pringle, JAS; Cannon, SR; (2000) Malignant round cell tumours of bone: atypical clinical and imaging features. SKELETAL RADIOL , 29 (11) 646 - 651.

Shah, EF; Woodside, J; Chatterjee, R; Stein, R; Saunders, C; (2000) The role of Zoladex in the prevention of ovarian damage during chemotherapy for primary breast cancer. BRIT J CANCER , 83 40 - 40.

Shamash, J; Lee, SM; Radford, JA; Rohatiner, AZS; Chang, J; Morgenstern, OR; Scarffe, JH; (2000) Patterns of relapse and subsequent management following high dose chemotherapy with autologous haemopoietic support in relapsed or refractory Hodgkin's lymphoma. Annals of Oncology , 11 (6) pp. 715-719.

Sharma, SK; Pedley, RB; Bhatia, J; Minton, N; Chester, KA; Begent, RHJ; (2000) In vivo characteristics of an engineered fusion protein for use in ADEPT. In: (pp. p. 172).

Sharma, SK; Pedley, RB; Bhatia, J; Minton, N; Chester, KA; Begent, RHJ; (2000) In vivo characteristics of an engineered fusion protein for use in ADEPT. BRIT J CANCER , 83 71 - 71.

Sharma, SK; Pedley, RB; Bhatia, J; Minton, N; Chester, KAAB; R, HJ; (2000) In vivo characteristics of a glycosylated fusion protein for prodrug activation. In: (Proceedings) Proceedings American Association for Cancer Research. (pp. 710-).

Short, S; (2000) UNSPECIFIED In: (Proceedings) Radiobiology 2000, Trivandrum, India.

Short, S; C, B; M, ; (2000) The treatment of malignant cerebral tumours. Hospital Medicine , 61 (11) pp. 772-777.

Short, SC; Traish, D; Dowe, A; Hines, F; Brada, M; (2000) UNSPECIFIED In: (Proceedings) 4th Congress of the European Association for Neuro-Oncology.

Smith, PG; Thomas, HD; Barlow, HC; Griffin, RJ; Golding, BT; Calvert, AH; Newell, DR; (2000) In vitro activity and in vivo pharmacology of two novel nucleoside transport inhibitors, NU3108 and NU3121. Clinical Cancer Research , 6 445 - ?.

Stein, RC; Waterfield, MD; (2000) PI3-kinase inhibition: a target for drug development? Mol Med Today , 6 (9) pp. 347-357.

T

Thomas, HD; Lind, MJ; Ford, J; Bleehen, N; Calvert, AH; Boddy, AV; (2000) Pharmacokinetics of carboplatin administered in combination with the bradykinin agonist Cereport (RMP-7) for the treatment of brain tumours. CANCER CHEMOTH PHARM , 45 (4) 284 - 290.

Tolner, B; Hartley, JA; Hochhauser, D; (2000) Modulation of topoisomerase II alpha expression at confluence by minor groove binders. BRIT J CANCER , 83 70 - 70.

ten Dam, GB; Zilch, CF; Wallace, D; Wieringa, B; Beverley, PCL; Poels, LG; Screaton, GR; (2000) Regulation of alternative splicing of CD45 by antagonistic effects of SR protein splicing factors. J IMMUNOL , 164 (10) 5287 - 5295.

V

Vanhaesebroeck, B; Alessi, DR; (2000) The PI3K-PDK1 connection: more than just a road to PKB. Biochem J , 346 Pt pp. 561-576.

Verweij, J; Lee, SM; Ruka, W; Buesa, J; Coleman, R; van, HR; Seynaeve, C; (2000) Randomised phase II study of docetaxel versus doxorubicin in first- and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: a study of the european organization for research and treatment of cancer soft tissue and bone sarcoma group. Journal of Clinical Oncology , 18 (10) pp. 2081-2086.

W

Westbury, C; Hines, F; Hawkes, E; Ashley, S; Brada, M; (2000) Advice on hair and scalp care during cranial radiotherapy: a prospective randomized trial. Radiother Oncol , 54 (2) pp. 109-116.

Westbury, C; Vini, L; Fisher, C; Harmer, C; (2000) Recurrent differentiated thyroid cancer without elevation of serum thyroglobulin. Thyroid , 10 (2) pp. 171-176. 10.1089/thy.2000.10.171.

White, AW; Almassy, R; Calvert, AH; Curtin, NJ; Griffin, RJ; Hostomsky, Z; Maegley, K; (2000) Resistance-modifying agents. 9. Synthesis and biological properties of benzimidazole inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase. J MED CHEM , 43 (22) 4084 - 4097. 10.1021/jm000950v.

This list was generated on Sun Mar 19 03:01:39 2017 GMT.